[Biolojic in Yahoo] Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007 to Eliminate Solid Tumors

LARKSPUR, Calif., March 21, 2022–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, has shared new preclinical data demonstrating solid tumor elimination when dosing AU-007, a monoclonal antibody computationally designed by Biolojic Design. Data were presented at a recent antibody biology and engineering conference.

Read more here.